Bandhan BSE Healthcare Index Fund vs Nippon India Pharma Fund
Direct Plan, Growth option · Data as on 30-10-2026
Bandhan BSE Healthcare Index Fund is an Index fund and Nippon India Pharma Fund is a Sectoral fund. In the year to 30-10-2026, Bandhan BSE Healthcare Index Fund (Direct) returned 12.0% and Nippon India Pharma Fund (Direct) returned 9.1%. Bandhan BSE Healthcare Index Fund charges 0.34% a year and Nippon India Pharma Fund 0.99% (Direct plans). Their portfolios overlap 59.3%: they hold 34 of the same securities.
Bandhan BSE Healthcare Index Fund
Index
- 1 year return
- 12.0%
- Expense ratio
- 0.34%
- NAV
- ₹11.58
Nippon India Pharma Fund
Sectoral
- 1 year return
- 9.1%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
Which is better, Bandhan BSE Healthcare Index or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Bandhan BSE Healthcare Index returned more over 1 year: 12.0% against 9.1%.
- Bandhan BSE Healthcare Index costs less: 0.34% a year against 0.99% (Direct plans).
- Nippon India Pharma fell less in its worst fall since 09-09-2024: −14.7% against −16.2%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹21 Cr.
- Their portfolios overlap 59.3%: 34 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Bandhan BSE Healthcare Index Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Bandhan Mutual Fund | Nippon India Mutual Fund |
| Category | Index | Sectoral |
| AUM | ₹21 Cr (31-08-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹11.58 (Direct) | ₹625.46 (Direct) |
| Expense ratio (Direct) | 0.34% | 0.99% |
| Expense ratio (Regular) | 1.15% | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 06-09-2024 | 05-06-2004 |
| Minimum investment | ₹1,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Abhishek Jain | Sailesh Raj Bhan |
| Exit load | • 0.25% if redeemed on or before 15 days from the allotment date. • Nil if redeemed after 15 days from allotment date. | Exit load of 1% if redeemed within 1 month. |
Bandhan BSE Healthcare Index vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Bandhan BSE Healthcare Index Fund (Direct) | +0.22% | −1.08% | +12.61% | +11.96% | -- | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
Bandhan BSE Healthcare Index vs Nippon India Pharma: Year-wise Returns
| Year | Bandhan BSE Healthcare IndexBandhan BSE Healthcare Index | Nippon India PharmaNippon India Pharma | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +14.73% | +9.76% | +15.08% |
| 2025 | −2.98% | −2.46% | −2.72% |
| 2024 | -- | +35.26% | +44.30% |
| 2023 | -- | +40.36% | +37.97% |
| 2022 | -- | −9.06% | −11.50% |
| 2021 | -- | +25.12% | +21.54% |
Bandhan BSE Healthcare Index vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 1-year holding period, 284 of them, one for each trading day from 09-09-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Bandhan BSE Healthcare Index Fund (Direct)
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
to
Oct 2025Dec 2024
to
Dec 2025Mar 2025
to
Mar 2026May 2025
to
May 2026Jul 2025
to
Jul 2026Sept 2025
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bandhan BSE Healthcare Index | 15.5 | 26.8 | 20.1 | 28.2 | 9.5 | 0.0 | 0.0 | 6.9% | 7.2% | −4.0% | 19.1% | 0% |
| Nippon India Pharma | 15.7 | 28.6 | 31.8 | 22.9 | 1.1 | 0.0 | 0.0 | 5.7% | 5.9% | −4.3% | 15.4% | 26% |
| BSE Healthcare TRI | 14.4 | 26.1 | 19.7 | 28.2 | 11.6 | 0.0 | 0.0 | 7.3% | 7.5% | −3.7% | 19.5% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 09-09-2024. Past returns do not promise future returns.
Bandhan BSE Healthcare Index vs Nippon India Pharma: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 09-09-2024 to 30-10-2026: 26 instalments, ₹2,60,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Bandhan BSE Healthcare IndexBandhan BSE Healthcare Index Fund (Direct) | ₹2,60,000 | ₹2,95,489 | ₹35,489 | 11.9% |
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹2,60,000 | ₹2,83,879 | ₹23,879 | 8.1% |
Bandhan BSE Healthcare IndexBandhan BSE Healthcare Index Fund (Direct)
Nippon India PharmaNippon India Pharma Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Bandhan BSE Healthcare Index vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Bandhan BSE Healthcare Index Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +11.96% | +9.05% |
| Standard deviation | 13.61% | 12.27% |
| Sharpe ratio | 0.49 | 0.31 |
| Sortino ratio | 0.72 | 0.45 |
| Maximum drawdown | −10.0% (23-10-2026) | −9.6% (23-10-2026) |
| Beta | 1.00 | 0.87 |
| Alpha | −0.41% | −2.40% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Bandhan BSE Healthcare Index Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +7.26% | +17.18% |
| Standard deviation | 14.58% | 15.19% |
| Sharpe ratio | 0.11 | 0.73 |
| Sortino ratio | 0.15 | 1.06 |
| Maximum drawdown | −16.2% (28-02-2025) | −24.0% (29-05-2017) |
| Beta | 1.00 | 0.85 |
| Alpha | −0.33% | +3.72% |
From daily NAVs, 09-09-2024 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Bandhan BSE Healthcare Index Fund (Direct)
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Bandhan BSE Healthcare Index Fund (Direct) | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
| Nippon India Pharma Fund (Direct) | −14.7% | 02-01-2025 | 28-02-2025 | 24-07-2025 | 5 months | −4.3% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 09-09-2024, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Bandhan BSE Healthcare Index Fund (Direct)
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund (Direct) | 99% | 101% | 0.04% |
| Nippon India Pharma Fund (Direct) | 88% | 99% | 3.58% |
From month-end values since 09-09-2024. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Bandhan BSE Healthcare Index vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: Bandhan BSE Healthcare Index Fund, August 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 59.3%
- Held by both
- 34
- Only in Bandhan BSE Healthcare Index
- 91
- Only in Nippon India Pharma
- 2
| Security | % of Bandhan BSE Healthcare Index | % of Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 12.95% | 11.71% |
| Divi's Laboratories Limited | 7.22% | 7.10% |
| Cipla Limited | 4.91% | 6.01% |
| Apollo Hospitals Enterprise Limited | 5.55% | 4.89% |
| Dr. Reddy's Laboratories Limited | 4.35% | 5.45% |
| Lupin Limited | 3.24% | 6.17% |
| Max Healthcare Institute Limited | 4.62% | 2.70% |
| Alkem Laboratories Limited | 1.92% | 1.82% |
| IPCA Laboratories Limited | 1.69% | 2.87% |
| Aurobindo Pharma Limited | 2.89% | 1.65% |
| Mankind Pharma Limited | 1.64% | 4.38% |
| Gland Pharma Limited | 1.40% | 2.53% |
| Sai Life Sciences Limited | 1.21% | 3.92% |
| Fortis Healthcare Limited | 2.90% | 1.13% |
| Biocon Limited | 1.77% | 1.01% |
| Ajanta Pharma Limited | 0.94% | 3.61% |
| Dr. Lal Path Labs Limited | 0.92% | 2.17% |
| Piramal Pharma Limited | 0.82% | 2.24% |
| Abbott India Limited | 0.81% | 2.32% |
| Narayana Hrudayalaya Limited | 0.81% | 1.61% |
| Anthem Biosciences Limited | 0.77% | 1.19% |
| GlaxoSmithKline Pharmaceuticals Limited | 0.76% | 3.11% |
| Syngene International Limited | 0.47% | 1.40% |
| Vijaya Diagnostic Centre Limited | 0.45% | 2.62% |
| Pfizer Limited | 0.43% | 1.35% |
| Emcure Pharmaceuticals Limited | 0.39% | 1.36% |
| AstraZeneca Pharma India Limited | 0.27% | 0.42% |
| Thyrocare Technologies Limited | 0.23% | 2.24% |
| Concord Biotech Limited | 0.30% | 0.17% |
| Sanofi India Limited | 0.17% | 1.00% |
| Sanofi Consumer Healthcare India Limited | 0.17% | 0.89% |
| Akums Drugs and Pharmaceuticals Limited | 0.16% | 1.21% |
| Indoco Remedies Limited | 0.06% | 0.48% |
| Suraksha Diagnostic Limited | 0.04% | 1.51% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 59.3% means 59.3% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Bandhan BSE Healthcare Index Fund
| Security | % of fund |
|---|---|
| Laurus Labs Limited | 4.48% |
| Torrent Pharmaceuticals Limited | 4.36% |
| Glenmark Pharmaceuticals Limited | 2.28% |
| Zydus Lifesciences Limited | 1.79% |
| Aster DM Quality Care Limited | 1.22% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| MedPlus Health Services Limited | 2.53% |
| Molbio Diagnostics Limited | 0.54% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Bandhan BSE Healthcare Index | Nippon India Pharma |
|---|---|---|
| Equity | 100.1% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | -0.1% | 2.7% |
Market cap of stocks
| Market cap | Bandhan BSE Healthcare Index | Nippon India Pharma |
|---|---|---|
| Large Cap | 35.0% | 29.7% |
| Mid Cap | 38.9% | 39.0% |
| Small Cap | 25.9% | 28.0% |
| Not on AMFI's list | 0.3% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Bandhan BSE Healthcare Index | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 77.1% | 74.0% |
| Healthcare Services | 22.5% | 20.3% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Bandhan BSE Healthcare Index vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Bandhan BSE Healthcare Index Fund | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.34% | 0.99% |
| Base expense ratio (Direct) | 0.19% | 0.79% |
| Total expense ratio (Regular) | 1.15% | 1.85% |
| Base expense ratio (Regular) | 0.88% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Bandhan BSE Healthcare Index Fund vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between Bandhan BSE Healthcare Index Fund and Nippon India Pharma Fund?
Bandhan BSE Healthcare Index Fund is an Index fund, Nippon India Pharma Fund is a Sectoral fund, run by Bandhan Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 59.3%. Bandhan BSE Healthcare Index Fund charges 0.34% a year and Nippon India Pharma Fund 0.99%.
Which has given higher returns, Bandhan BSE Healthcare Index Fund or Nippon India Pharma Fund?
Over 1 year: Bandhan BSE Healthcare Index Fund +11.96%, Nippon India Pharma Fund +9.05%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Bandhan BSE Healthcare Index Fund or Nippon India Pharma Fund?
Bandhan BSE Healthcare Index Fund charges less: 0.34% a year against 0.99%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Bandhan BSE Healthcare Index Fund and Nippon India Pharma Fund overlap?
59.3%. They hold 34 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, CIPLA. From each fund's latest monthly portfolio.
Which is riskier, Bandhan BSE Healthcare Index Fund or Nippon India Pharma Fund?
On SEBI's riskometer, Bandhan BSE Healthcare Index Fund is rated Very High and Nippon India Pharma Fund Very High. Over 1 years, the standard deviation of daily returns was 13.61% and 12.27% a year.
Can I invest in both Bandhan BSE Healthcare Index Fund and Nippon India Pharma Fund?
Yes. 59.3% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Bandhan BSE Healthcare Index Fund and Nippon India Pharma Fund?
Bandhan BSE Healthcare Index Fund: Abhishek Jain. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.